Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients

References

1. 1.↵
   2. Bumingham Z,
   3. Hashibe M,
   4. Spector L,
   5. Schiffman JD.

   The epidemiology of sarcoma. Clin Sarcoma Res. 2012; 2: 14.

   OpenUrlCrossRefPubMed
2. 2.↵
   2. Christopher D.M.
   3. Fletcher JAB,
   4. Pancras C.W.

   Hogendoorn, Frodrik Mertens. Who classification of tumours of soft tissue and bone. Lyon: IARC. 2013.
3. 3.↵
   2. Korc M,
   3. Friesel RE.

   The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets. 2009; 9: 639–51.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   2. Wesche J,
   3. Haglund K,
   4. Haugsten EM.

   Fibroblast growth factors and their receptors in cancer. Biochem J. 2011; 437: 199–213.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   2. Kwabi-Addo B,
   3. Ozen M,
   4. Ittmann M.

   The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer. 2004; 11: 709–24.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   2. Beenken A,
   3. Mohammadi M.

   The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8: 235-53.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   2. Lindner V,
   3. Majack RA,
   4. Reidy MA.

   Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest. 1990; 85: 2004–8.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.
   2. Halaban R.

   Growth factors and melanomas. Semin Oncol. 1996; 23: 673–81.

   OpenUrlPubMedWeb of Science
9. 9.
   2. Bian XW,
   3. Du LL,
   4. Shi JQ,
   5. Cheng YS,
   6. Liu FX.

   Correlation of BFGF, FGFR-1 and VEGF expression with vascularity and malignancy of human astrocytomas. Anal Quant Cytol Histol. 2000; 22: 267–74.

   OpenUrlPubMed
10. 10.
    2. Relf M,
    3. LeJeune S,
    4. Scott PA,
    5. Fox S,
    6. Smith K,
    7. Leek R, et al.

    Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997; 57: 963–9.

    OpenUrlAbstract/FREE Full Text
11. 11.
    2. Yamanaka Y,
    3. Friess H,
    4. Buchler M,
    5. Beger HG,
    6. Uchida E,
    7. Onda M, et al.

    Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res. 1993; 53: 5289–96.

    OpenUrlAbstract/FREE Full Text
12. 12.
    2. Berger W,
    3. Setinek U,
    4. Mohr T,
    5. Kindas-Mugge I,
    6. Vetterlein M,
    7. Dekan G, et al.

    Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. Int J Cancer. 1999; 83: 415–23.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.
    2. Gazzaniga P,
    3. Gandini O,
    4. Gradilone A,
    5. Silvestri I,
    6. Giuliani L,
    7. Magnanti M, et al.

    Detection of basic fibroblast growth factor MRNA in urinary bladder cancer: Correlation with local relapses. Int J Oncol. 1999; 14: 1123–7.

    OpenUrlPubMedWeb of Science
14. 14.
    2. Dellacono FR,
    3. Spiro J,
    4. Eisma R,
    5. Kreutzer D.

    Expression of basic fibroblast growth factor and its receptors by head and neck squamous carcinoma tumor and vascular endothelial cells. Am J Surg. 1997; 174: 540–4.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    2. Huang X,
    3. Yu C,
    4. Jin C,
    5. Yang C,
    6. Xie R,
    7. Cao D, et al.

    Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog. 2006; 45: 934–42.

    OpenUrlCrossRefPubMed
16. 16.↵
    2. Ramos C,
    3. Becerril C,
    4. Montano M,
    5. Garcia-De-Alba C,
    6. Ramirez R,
    7. Checa M, et al.

    FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway. Am J Physiol Lung Cell Mol Physiol. 2010; 299: L222–31.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    2. Jouanneau J,
    3. Plouet J,
    4. Moens G,
    5. Thiery JP.

    FGF-2 and FGF-1 expressed in rat bladder carcinoma cells have similar angiogenic potential but different tumorigenic properties in vivo. Oncogene. 1997; 14: 671–6.

    OpenUrlCrossRefPubMed
18. 18.↵
    2. Nakao Y,
    3. Mitsuyasu T,
    4. Kawano S,
    5. Nakamura N,
    6. Kanda S,
    7. Nakamura S.

    Fibroblast growth factors 7 and 10 are involved in ameloblastoma proliferation via the mitogen-activated protein kinase pathway. Int J Oncol. 2013; 43: 1377–84.

    OpenUrlPubMed
19. 19.↵
    2. Liu R,
    3. Huang S,
    4. Lei Y,
    5. Zhang T,
    6. Wang K,
    7. Liu B, et al.

    FGF8 promotes colorectal cancer growth and metastasis by activating YAP1. Oncotarget. 2015; 6: 935–52.

    OpenUrlCrossRef
20. 20.↵
    2. Sun C,
    3. Fukui H,
    4. Hara K,
    5. Zhang X,
    6. Kitayama Y,
    7. Eda H, et al.

    FGF9 from cancer-associated fibroblasts is a possible mediator of invasion and anti-apoptosis of gastric cancer cells. BMC Cancer. 2015; 15: 333.

    OpenUrl
21. 21.↵
    2. Okada T,
    3. Murata K,
    4. Hirose R,
    5. Matsuda C,
    6. Komatsu T,
    7. Ikekita M, et al.

    Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells. Sci Rep. 2013; 3: 2899.

    OpenUrlCrossRef
22. 22.↵
    2. Uriarte I,
    3. Latasa MU,
    4. Carotti S,
    5. Fernandez-Barrena MG,
    6. Garcia-Irigoyen O,
    7. Elizalde M, et al.

    Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. Int J Cancer. 2015; 136: 2469–75.

    OpenUrlCrossRefPubMed
23. 23.↵
    2. Basu M,
    3. Mukhopadhyay S,
    4. Chatterjee U,
    5. Roy SS.

    FGF16 promotes invasive behavior of skov-3 ovarian cancer cells through activation of mitogen-activated protein kinase (MAPK) signaling pathway. J Biol Chem. 2014; 289: 1415–28.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    2. Jarosz M,
    3. Robbez-Masson L,
    4. Chioni AM,
    5. Cross B,
    6. Rosewell I,
    7. Grose R.

    Fibroblast growth factor 22 is not essential for skin development and repair but plays a role in tumorigenesis. PLoS One. 2012; 7: e39436.
25. 25.↵
    2. Takahashi JA,
    3. Fukumoto M,
    4. Igarashi K,
    5. Oda Y,
    6. Kikuchi H,
    7. Hatanaka M.

    Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg. 1992; 76: 792–8.

    OpenUrlPubMedWeb of Science
26. 26.↵
    2. Acevedo VD,
    3. Ittmann M,
    4. Spencer DM.

    Paths of FGFR-driven tumorigenesis. Cell Cycle. 2009; 8: 580–8.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    2. Javerzat S,
    3. Auguste P,
    4. Bikfalvi A.

    The role of fibroblast growth factors in vascular development. Trends Mol Med. 2002; 8: 483–9.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    2. Xu Q,
    3. Gao S,
    4. Liu J.

    [the expression of caspase-3, BFGF and MVD in laryngeal squamous cell carcinoma and the relationship among them]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2013; 27: 1084–7.

    OpenUrl
29. 29.↵
    2. Zhou B,
    3. Ma R,
    4. Si W,
    5. Li S,
    6. Xu Y,
    7. Tu X, et al.

    Microrna-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett. 2013; 333: 159–69.

    OpenUrlCrossRefPubMedWeb of Science
30. 30.↵
    2. Olsen SK,
    3. Ibrahimi OA,
    4. Raucci A,
    5. Zhang F,
    6. Eliseenkova AV,
    7. Yayon A, et al.

    Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci U S A. 2004; 101: 935–40.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    2. Johnson DE,
    3. Williams LT.

    Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 1993; 60: 1–41.

    OpenUrlPubMedWeb of Science
32. 32.
    2. Itoh N,
    3. Omitz DM.

    Evolution of the FGF and FGFR gene families. Trends Genet. 2004; 20: 563–9.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.
    2. Matsumoto E,
    3. Sasaki S,
    4. Kinoshita H,
    5. Kito T,
    6. Ohta H,
    7. Konishi M, et al.

    Angiotensin II-induced cardiac hypertrophy and fibrosis are promoted in mice lacking FGF16. Genes Cells. 2013; 18: 544–53.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.
    2. Hamidouche Z,
    3. Fromigue O,
    4. Nuber U,
    5. Vaudin P,
    6. Pages JC,
    7. Ebert R, et al.

    Autocrine fibroblast growth factor 18 mediates dexamethasone-induced osteogenic differentiation of murine mesenchymal stem cells. J Cell Physiol. 2010; 224: 509–15.

    OpenUrlCrossRefPubMed
35. 35.↵
    2. Itoh N,
    3. Ohta H.

    Roles of FGF20 in dopaminergic neurons and parkinson's disease. Front Mol Neurosci. 2013; 6: 15.

    OpenUrl
36. 36.
    2. Kharitonenkov A,
    3. Dunbar JD,
    4. Bina HA,
    5. Bright S,
    6. Moyers JS,
    7. Zhang C, et al.

    FGF-21/FGF-21 receptor interaction and activation is determined by betaklotho. J Cell Physiol. 2008; 215: 1–7.

    OpenUrlCrossRefPubMedWeb of Science
37. 37.
    2. Gattineni J,
    3. Alphonse P,
    4. Zhang Q,
    5. Mathews N,
    6. Bates CM,
    7. Baum M.

    Regulation of renal phosphate transport by FGF23 is mediated by fgfr1 and FGFR4. Am J Physiol Renal Physiol. 2014; 306: F351–8.

    OpenUrlCrossRefPubMedWeb of Science
38. 38.
    2. Umemori H,
    3. Linhoff MW,
    4. Ornitz DM,
    5. Sanes JR.

    FGF22 and its close relatives are presynaptic organizing molecules in the mammalian brain. Cell. 2004; 118: 257–70.

    OpenUrlCrossRefPubMedWeb of Science
39. 39.
    2. Fortin D,
    3. Rom E,
    4. Sun H,
    5. Yayon A,
    6. Bansal R.

    Distinct fibroblast growth factor (FGF)/FGF receptor signaling pairs initiate diverse cellular responses in the oligodendrocyte lineage. J Neurosci. 2005; 25: 7470–9.

    OpenUrlAbstract/FREE Full Text
40. 40.↵
    2. Sonvilla G,
    3. Allerstorfer S,
    4. Heinzle C,
    5. Stattner S,
    6. Karner J,
    7. Klimpfinger M, et al.

    Fibroblast growth factor receptor 3-IIIC mediates colorectal cancer growth and migration. Br J Cancer. 2010; 102: 1145–56.

    OpenUrlCrossRefPubMedWeb of Science
41. 41.
    2. Fu T,
    3. Kim YC,
    4. Byun S,
    5. Kim DH,
    6. Seok S,
    7. Suino-Powell K, et al.

    FXR primes the liver for intestinal FGF15 signaling by transient induction of beta-klotho. Mol Endocrinol. 2016; 30: 92–103.

    OpenUrl
42. 42.
    2. Cinque L,
    3. Forrester A,
    4. Bartolomeo R,
    5. Svelto M,
    6. Venditti R,
    7. Montefusco S, et al.

    FGF signalling regulates bone growth through autophagy. Nature. 2015; 528: 272–5.

    OpenUrlCrossRefPubMed
43. 43.
    2. Xie MH,
    3. Holcomb I,
    4. Deuel B,
    5. Dowd P,
    6. Huang A,
    7. Vagts A, et al.

    Fgf-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine. 1999; 11: 729–35.

    OpenUrlCrossRefPubMedWeb of Science
44. 44.↵
    2. Ornitz DM,
    3. Xu J,
    4. Colvin JS,
    5. McEwen DG,
    6. MacArthur CA,
    7. Coulier F, et al.

    Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996; 271: 15292–7.

    OpenUrlAbstract/FREE Full Text
45. 45.↵
    2. Duchesne L,
    3. Tissot B,
    4. Rudd TR,
    5. Dell A,
    6. Fernig DG.

    N-glycosylation of fibroblast growth factor receptor 1 regulates ligand and heparan sulfate co-receptor binding. J Biol Chem. 2006; 281: 27178–89.

    OpenUrlAbstract/FREE Full Text
46. 46.↵
    2. Sleeman M,
    3. Fraser J,
    4. McDonald M,
    5. Yuan S,
    6. White D,
    7. Grandison P, et al.

    Identification of a new fibroblast growth factor receptor, FGFR5. Gene. 2001; 271: 171–82.

    OpenUrlCrossRefPubMedWeb of Science
47. 47.↵
    2. Silva PN,
    3. Altamentova SM,
    4. Kilkenny DM,
    5. Rocheleau JV.

    Fibroblast growth factor receptor like-1 (FGFRL1) interacts with shp-1 phosphatase at insulin secretory granules and induces beta-cell ERK1/2 protein activation. J Biol Chem. 2013; 288: 17859–70.

    OpenUrlAbstract/FREE Full Text
48. 48.↵
    2. Wakulich C,
    3. Jackson-Boeters L,
    4. Daley TD,
    5. Wysocki GP.

    Immunohistochemical localization of growth factors fibroblast growth factor-1 and fibroblast growth factor-2 and receptors fibroblast growth factor receptor-2 and fibroblast growth factor receptor-3 in normal oral epithelium, epithelial dysplasias, and squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002; 93: 573–9.

    OpenUrlPubMed
49. 49.↵
    2. Jang JH.

    Reciprocal relationship in gene expression between FGFR1 and FGFR3: Implication for tumorigenesis. Oncogene. 2005; 24: 945–8.

    OpenUrlCrossRefPubMed
50. 50.↵
    2. Haugsten EM,
    3. Wiedlocha A,
    4. Olsnes S,
    5. Wesche J.

    Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res. 2010; 8: 1439–52.

    OpenUrlAbstract/FREE Full Text
51. 51.↵
    2. Moosa S,
    3. Wollnik B.

    Altered FGF signalling in congenital craniofacial and skeletal disorders. Semin Cell Dev Biol. 2015;
52. 52.↵
    2. Eswarakumar VP,
    3. Lax I,
    4. Schlessinger J.

    Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005; 16: 139–49.

    OpenUrlCrossRefPubMedWeb of Science
53. 53.↵
    2. Vecchione A,
    3. Cooper HJ,
    4. Trim KJ,
    5. Akbarzadeh S,
    6. Heath JK,
    7. Wheldon LM.

    Protein partners in the life history of activated fibroblast growth factor receptors. Proteomics. 2007; 7: 4565–78.

    OpenUrlCrossRefPubMedWeb of Science
54. 54.↵
    2. Martinez N,
    3. Garcia-Dominguez CA,
    4. Domingo B,
    5. Oliva JL,
    6. Zarich N,
    7. Sanchez A, et al.

    Sprouty2 binds GRB2 at two different proline-rich regions, and the mechanism of erk inhibition is independent of this interaction. Cell Signal. 2007; 19: 2277–85.

    OpenUrlCrossRefPubMed
55. 55.
    2. Li C,
    3. Scott DA,
    4. Hatch E,
    5. Tian X,
    6. Mansour SL.

    Dusp6 (MKP3) is a negative feedback regulator of fgf-stimulated erk signaling during mouse development. Development. 2007; 134: 167–76.

    OpenUrlAbstract/FREE Full Text
56. 56.
    2. Kovalenko D,
    3. Yang X,
    4. Nadeau RJ,
    5. Harkins LK,
    6. Friesel R.

    Sef inhibits fibroblast growth factor signaling by inhibiting FGFR1 tyrosine phosphorylation and subsequent erk activation. J Biol Chem. 2003; 278: 14087–91.

    OpenUrlAbstract/FREE Full Text
57. 57.↵
    2. Mardakheh FK,
    3. Yekezare M,
    4. Machesky LM,
    5. Heath JK.

    Spred2 interaction with the late endosomal protein nbr1 down-regulates fibroblast growth factor receptor signaling. J Cell Biol. 2009; 187: 265–77.

    OpenUrlAbstract/FREE Full Text
58. 58.↵
    2. Bottcher RT,
    3. Pollet N,
    4. Delius H,
    5. Niehrs C.

    The transmembrane protein XFLRT3 forms a complex with FGF receptors and promotes FGF signalling. Nat Cell Biol. 2004; 6: 38–44.

    OpenUrlCrossRefPubMedWeb of Science
59. 59.↵
    2. Haines BP,
    3. Wheldon LM,
    4. Summerbell D,
    5. Heath JK,
    6. Rigby PW.

    Regulated expression of FLRT genes implies a functional role in the regulation of FGF signalling during mouse development. Dev Biol. 2006; 297: 14–25.

    OpenUrlCrossRefPubMedWeb of Science
60. 60.↵
    2. Ottaviani G,
    3. Jaffe N.

    The etiology of osteosarcoma. Cancer Treat Res. 2009; 152: 15–32.

    OpenUrlCrossRefPubMed
61. 61.↵
    2. Baird K,
    3. Davis S,
    4. Antonescu CR,
    5. Harper UL,
    6. Walker RL,
    7. Chen Y, et al.

    Gene expression profiling of human sarcomas: Insights into sarcoma biology. Cancer Res. 2005; 65: 9226–35.

    OpenUrlAbstract/FREE Full Text
62. 62.↵
    2. Hassan SE,
    3. Bekarev M,
    4. Kim MY,
    5. Lin J,
    6. Piperdi S,
    7. Gorlick R, et al.

    Cell surface receptor expression patterns in osteosarcoma. Cancer. 2012; 118: 740–9.

    OpenUrlPubMed
63. 63.↵
    2. Fernanda Amary M,
    3. Ye H,
    4. Berisha F,
    5. Khatri B,
    6. Forbes G,
    7. Lehovsky K, et al.

    Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy. Cancer Med. 2014; 3: 980–7.

    OpenUrl
64. 64.↵
    2. Ren T,
    3. Qing Y,
    4. Dai N,
    5. Li M,
    6. Qian C,
    7. Yang Y, et al.

    Apurinic/apyrimidinic endonuclease 1 induced upregulation of fibroblast growth factor 2 and its receptor 3 induces angiogenesis in human osteosarcoma cells. Cancer Sci. 2014; 105: 186–94.

    OpenUrl
65. 65.↵
    2. Leddy LR,
    3. Holmes RE.

    Chondrosarcoma of bone. Cancer Treat Res. 2014; 162: 117–30.

    OpenUrl
66. 66.↵
    2. Webster MK,
    3. Donoghue DJ.

    Fgfr activation in skeletal disorders: Too much of a good thing. Trends Genet. 1997; 13: 178–82.

    OpenUrlCrossRefPubMedWeb of Science
67. 67.↵
    2. Sahni M,
    3. Ambrosetti DC,
    4. Mansukhani A,
    5. Gertner R,
    6. Levy D,
    7. Basilico C.

    FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 1999; 13: 1361–6.

    OpenUrlAbstract/FREE Full Text
68. 68.↵
    2. Aikawa T,
    3. Segre GV,
    4. Lee K.

    Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-CDK2. J Biol Chem. 2001; 276: 29347–52.

    OpenUrlAbstract/FREE Full Text
69. 69.↵
    2. van Oosterwijk JG,
    3. Meijer D,
    4. van Ruler MA,
    5. van den Akker BE,
    6. Oosting J,
    7. Krenacs T, et al.

    Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFbeta as potential targets. Am J Pathol. 2013; 182: 1347–56.

    OpenUrl
70. 70.↵
    2. De Giovanni C,
    3. Landuzzi L,
    4. Nicoletti G,
    5. Lollini PL,
    6. Nanni P.

    Molecular and cellular biology of rhabdomyosarcoma. Future Oncol. 2009; 5: 1449–75.

    OpenUrlCrossRefPubMed
71. 71.↵
    2. Taylor JGt,
    3. Cheuk AT,
    4. Tsang PS,
    5. Chung JY,
    6. Song YK,
    7. Desai K, et al.

    Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest. 2009; 119: 3395–407.

    OpenUrlPubMedWeb of Science
72. 72.↵
    2. Crose LE,
    3. Etheridge KT,
    4. Chen C,
    5. Belyea B,
    6. Talbot LJ,
    7. Bentley RC, et al.

    FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res. 2012; 18: 3780–90.

    OpenUrlAbstract/FREE Full Text
73. 73.↵
    2. Wachtel M,
    3. Rakic J,
    4. Okoniewski M,
    5. Bode P,
    6. Niggli F,
    7. Schafer BW.

    FGFR4 signaling couples to bim and not bmf to discriminate subsets of alveolar rhabdomyosarcoma cells. Int J Cancer. 2014; 135: 1543–52.

    OpenUrl
74. 74.↵
    2. Wang X,
    3. Asmann YW,
    4. Erickson-Johnson MR,
    5. Oliveira JL,
    6. Zhang H,
    7. Moura RD, et al.

    High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma. Genes Chromosomes Cancer. 2011; 50: 849–58.

    OpenUrlCrossRefPubMedWeb of Science
75. 75.↵
    2. Zhang K,
    3. Chu K,
    4. Wu X,
    5. Gao H,
    6. Wang J,
    7. Yuan YC, et al.

    Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma. Cancer Res. 2013; 73: 1298-307.

    OpenUrlAbstract/FREE Full Text
76. 76.↵
    2. Kunstlinger H,
    3. Fassunke J,
    4. Schildhaus HU,
    5. Brors B,
    6. Heydt C,
    7. Ihle MA, et al.

    FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro. Oncotarget. 2015; 6: 20215–30.

    OpenUrlCrossRefPubMed
77. 77.↵
    2. Ishibe T,
    3. Nakayama T,
    4. Okamoto T,
    5. Aoyama T,
    6. Nishijo K,
    7. Shibata KR, et al.

    Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: Potential application of signal inhibitors to molecular target therapy. Clin Cancer Res. 2005; 11: 2702–12.

    OpenUrlAbstract/FREE Full Text
78. 78.↵
    2. Girnita L,
    3. Girnita A,
    4. Wang M,
    5. Meis-Kindblom JM,
    6. Kindblom LG,
    7. Larsson O.

    A link between basic fibroblast growth factor (BFGF) and EWS/FLI-1 in ewing's sarcoma cells. Oncogene. 2000; 19: 4298-301.

    OpenUrlCrossRefPubMedWeb of Science
79. 79.↵
    2. Westwood G,
    3. Dibling BC,
    4. Cuthbert-Heavens D,
    5. Burchill SA.

    Basic fibroblast growth factor (BFGF)-induced cell death is mediated through a caspase-dependent and p53-independent cell death receptor pathway. Oncogene. 2002; 21: 809–24.

    OpenUrlCrossRefPubMedWeb of Science
80. 80.↵
    2. Ishigami T,
    3. Hida Y,
    4. Matsudate Y,
    5. Murao K,
    6. Kubo Y.

    The involvement of fibroblast growth factor receptor signaling pathways in dermatofibroma and dermatofibrosarcoma protuberans. J Med Invest. 2013; 60: 106–13.

    OpenUrlCrossRef
81. 81.↵
    2. Kilvaer TK,
    3. Valkov A,
    4. Sorbye SW,
    5. Smeland E,
    6. Bremnes RM,
    7. Busund LT, et al.

    Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients. J Transl Med. 2011; 9: 104.

    OpenUrlCrossRefPubMed
82. 82.↵
    2. Noonan S,
    3. Man Wong K,
    4. Jimeno A.

    Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer. Drugs Today (Barc). 2015; 51: 357–66.

    OpenUrlPubMed
83. 83.↵
    2. Soria JC,
    3. DeBraud F,
    4. Bahleda R,
    5. Adamo B,
    6. Andre F,
    7. Dienstmann R, et al.

    Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol. 2014; 25: 2244–51.

    OpenUrlCrossRefPubMed
84. 84.↵
    2. Eisen T,
    3. Loembe AB,
    4. Shparyk Y,
    5. MacLeod N,
    6. Jones RJ,
    7. Mazurkiewicz M, et al.

    A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results. Br J Cancer. 2015; 113: 1140–7.

    OpenUrl
85. 85.
    2. Konecny GE,
    3. Finkler N,
    4. Garcia AA,
    5. Lorusso D,
    6. Lee PS,
    7. Rocconi RP, et al.

    Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: A non-randomised, open-label, two-group, two-stage, phase 2 study. Lancet Oncol. 2015; 16: 686–94.

    OpenUrl
86. 86.
    2. du Bois A,
    3. Kristensen G,
    4. Ray-Coquard I,
    5. Reuss A,
    6. Pignata S,
    7. Colombo N, et al.

    Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (ago-ovar 12): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016; 17: 78–89.

    OpenUrlCrossRefPubMed
87. 87.↵
    2. Cortes JE,
    3. Kim DW,
    4. Pinilla-Ibarz J,
    5. le Coutre P,
    6. Paquette R,
    7. Chuah C, et al.

    A phase 2 trial of ponatinib in philadelphia chromosome-positive leukemias. N Engl J Med. 2013; 369: 1783–96.

    OpenUrlCrossRefPubMedWeb of Science
88. 88.↵
    2. Xiang J,
    3. Tang J,
    4. Song C,
    5. Yang Z,
    6. Hirst DG,
    7. Zheng QJ, et al.

    Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma. Cytotherapy. 2009; 11: 516–26.

    OpenUrl
89. 89.↵
    2. Ettrich TJ,
    3. Seufferlein T.

    Regorafenib. Recent Results Cancer Res. 2014; 201: 185–96.

    OpenUrl
90. 90.↵
    2. Li SQ,
    3. Cheuk AT,
    4. Shern JF,
    5. Song YK,
    6. Hurd L,
    7. Liao H, et al.

    Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (ap24534). PLoS One. 2013; 8: e76551.